Immunic Ownership

IMUX -  USA Stock  

USD 8.43  0.06  0.71%

Some institutional investors establish a significant position in stocks such as Immunic in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Immunic, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Please see Risk vs Return Analysis.

Immunic Ownership Allocation 

 
Refresh
Preferred Dividends Income Statement Impact is likely to drop to about 8.7 M in 2021. Weighted Average Shares is likely to rise to about 16.9 M in 2021. Weighted Average Shares Diluted is likely to rise to about 16.9 M in 2021.
Immunic secures a total of 21.75 Million outstanding shares. Immunic secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Immunic Stock Ownership Analysis

About 25.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.13. Some equities with similar Price to Book (P/B) outperform the market in the long run. Immunic recorded a loss per share of 2.81. The entity had not issued any dividends in recent years. The firm had a split on the 15th of April 2019. Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people. To learn more about Immunic call Daniel Vitt at 332 255 9818 or check out http://www.immunic-therapeutics.com.
Besides selling stocks to institutional investors, Immunic also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Immunic's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Immunic's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Immunic Quarterly Share Based Compensation

1.51 MillionShare
About 25.0% of Immunic are currently held by insiders. Unlike Immunic's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Immunic's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%.

Immunic SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Immunic prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Immunic investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Immunic specific information freely available to individual and institutional investors to make a timely investment decision.
15th of October 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
19th of February 2021
Unclassified Corporate Event
View

Immunic Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Immunic is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunic backward and forwards among themselves. Immunic's institutional investor refers to the entity that pools money to purchase Immunic's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Golden Green IncCommon Shares87.1 K771 K
Omega Fund Management LlcCommon Shares1.8 M21.9 M
Fmr LlcCommon Shares1.2 M14.6 M
Blackrock IncCommon Shares1.1 M13.8 M
Rtw Investments LpCommon Shares920.8 K11.3 M
Vanguard Group IncCommon Shares711.8 K8.7 M
Artal Group SaCommon Shares700 K8.6 M
Note, although Immunic's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Immunic Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunic insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Immunic without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Probability Of Bankruptcy Now

   

Probability Of Bankruptcy

Get analysis of equity chance of financial distress in the next 2 years
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunic using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Note that the Immunic information on this page should be used as a complementary analysis to other Immunic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Immunic Stock analysis

When running Immunic price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine Immunic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.